OR WAIT 15 SECS
Novotech, Australia?s largest clinical CRO with offices throughout Asia, announced today the expansion of services to China with a Novotech office in Shanghai, a wholly owned entity with local staff. Shanghai is the ninth Novotech office in Asia.
Novotech, Australia’s largest clinical CRO
with offices throughout Asia, announced today the expansion of services to
China with a Novotech office in Shanghai, a wholly owned entity with local staff.
Shanghai is the ninth Novotech office in Asia.
Novotech has a proven track record in the region and is sought out by biotech
and pharma companies for its specialist clinical research services, and access to
its diverse patient populations across Asia.
The CRO has been actively involved in hundreds of drug development programs
for US and EU registration over the past 18 years.
Novotech Asia COO, Dr. John Moller said China is now the largest clinical trial
destination in Asia, and the 5th largest in the world.
“China’s increasingly sophisticated clinical trial infrastructure and its 1.36 billion
population with a high incidence of chronic diseases, makes it a compelling
choice for our EU and USA biotech and pharma clients,” said Dr. Moller.
“The sheer numbers and scale in China is unprecedented. We are seeing
hospital-based clinical trial units with up to 4,000 beds,” said Dr Moller.
Dr. Moller said Novotech was encouraged also by China’s commitment to
growing the research sector with an USD$18 billion funding allocation for biotech
and pharma as part of their 5-year plan.
Novotech CEO Alek Safarian said feedback and demand from Novotech’s USA
and EU biotech and pharma sponsors was the driver to start offering its worldclass
research services in China.
“China spends $63 billion on pharmaceuticals annually so biotechs and pharma
companies are naturally keen to establish a presence early in the development
pipeline,” said Safarian.
Novotech is an internationally recognized full service CRO known for its
experience across Australia, New Zealand, Asia and South Africa, representing
emerging markets with a population base of over 3 billion people.
About Novotech www.novotech-cro.com
Established in 1996 and headquartered in Sydney, Novotech has a strong
presence in the Asia Pacific region, running clinical trials in all key regional
markets including China, India, Australia, Taiwan and Korea. Novotech also has
offices in South Africa.
Novotech also has worldwide reach through the company's network of strategic
partners. Novotech - described by Frost & Sullivan as the best in its industry
class for Australia-based CROs and recipient of the ARCS ANZ Clinical Trials
award in 2013 for “Best CRO” - brings its global reputation for high quality service
and regional expertise to the high-growth Asia Pacific area. For more information,
please visit www.novotech-cro.com.
Novotech provides the following clinical development services across all clinical
trial phases and therapeutic areas including Feasibility assessments; Ethics
Committee and submissions, clinical monitoring, data management, statistical
analysis, report write-up to ICH requirements, project management and vendor